CA
AMPH icon

Crewe Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Crewe Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-71
Closed -$3.12K – 942
2024
Q1 		$3.12K Hold
71
– – ﹤0.01% 810
2023
Q4 		$4.39K Buy
+71
New +$3.73K ﹤0.01% 259

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crewe Advisors's AMPH Position: Q2 2024 in Review

Crewe Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2024, closing a stake of 71 shares — an estimated $3.12K sold.

Crewe Advisors first reported a position in AMPH in Q4 2023 and held it in 2 quarters. The position peaked at $4.39K in Q4 2023. 269 funds tracked by Wall St. Rank hold AMPH as of Q2 2024.

  • Crewe Advisors reported no remaining Amphastar Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Crewe Advisors sold 71 Amphastar Pharmaceuticals shares in Q2 2024, an estimated $3.12K.
  • Crewe Advisors first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Crewe Advisors's Amphastar Pharmaceuticals position peaked at $4.39K in Q4 2023.
  • 269 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2024.

Based on Crewe Advisors's 13F filing for Q2 2024, filed 29 Jul 2024.